Health Care [ 10/12 ] | Biotechnology [ 64/73 ]
NASDAQ | Common Stock
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States.
Its drug delivery and antisense technology is the DNAbilize, a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge.
The company's lead drug candidate is the Prexigebersen (BP1001), which is in phase 2 clinical trial for the treatment of untreated acute myeloid leukemia (AML).
It is also developing BP1001-A, which is in phase 1 clinical trial for treatment of solid tumors, including ovarian, endometrial and pancreatic cancer, as well as in preclinical trial to treat obesity and related metabolic diseases; Liposomal Bcl-2 (BP1002), which is in phase 1 clinical trial to treat refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003), which is preclinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and AML.
Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 25 | -0.40 Increased by +91.80% | -0.38 Decreased by -5.26% |
| Mar 6, 25 | -0.07 Increased by +99.01% | -0.37 Increased by +81.08% |
| Nov 13, 24 | -0.70 Decreased by -118.75% | -1.02 Increased by +31.37% |
| Aug 14, 24 | -1.16 Decreased by -118.87% | -1.54 Increased by +24.68% |
| May 14, 24 | -4.88 Decreased by -639.39% | -4.54 Decreased by -7.49% |
| Mar 7, 24 | -7.05 Decreased by -1.26 K% | -5.40 Decreased by -30.56% |
| Nov 13, 23 | -0.32 Increased by +34.69% | -0.34 Increased by +5.88% |
| Aug 14, 23 | -0.53 Decreased by -26.19% | -0.52 Decreased by -1.92% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -2.85 M Increased by +9.66% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -2.75 M Increased by +18.36% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.12 M Increased by +33.89% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.87 M Increased by +55.86% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -3.16 M Increased by +39.91% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 274.00 K Increased by +N/A% | -3.37 M Increased by +14.55% | Decreased by -1.23 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.20 M Increased by +9.22% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -4.23 M Decreased by -40.85% | Decreased by N/A% Decreased by N/A% |